Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia
The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safet...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| シリーズ: | Hematology/Oncology and Stem Cell Therapy |
| 主題: | |
| オンライン･アクセス: | https://journals.lww.com/10.56875/2589-0646.1039 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|